Full Breakdown
Trump Administration Launches New Drug Pricing Model for Medicaid
11/7/2025, 11:56:04 PM
Overview of the GENEROUS Model
On November 6, 2025, the Trump administration announced the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model, a new initiative aimed at reducing prescription drug costs for Medicaid beneficiaries by aligning prices with those in other developed nations. The model, set to launch in January 2026 and run for five years, allows participating state Medicaid programs to purchase select drugs at "most-favored-nation" rates, which are the lowest prices paid in countries such as the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland.
Key Features of the Program
The Centers for Medicare and Medicaid Services (CMS) will negotiate prices with drug manufacturers, who will be required to provide additional rebates to ensure that Medicaid prices match those in the aforementioned countries. States that opt into the program will implement standardized coverage criteria, ensuring uniform access for Medicaid beneficiaries. In 2024, total Medicaid spending on prescription drugs exceeded $100 billion, highlighting the urgency for reform.
Implications for Drug Prices
Under the GENEROUS model, participating states can expect to pay significantly lower prices for drugs. For instance, the monthly cost for popular GLP-1 medications, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, will be reduced to $245 for Medicare and Medicaid patients. The administration also announced that these drugs will be available through a new government website, TrumpRx, starting at $350 per month, with prices expected to trend down to $245 over two years.
Official Statements & Responses
Health and Human Services Secretary Robert F. Kennedy Jr. stated, “Thanks to President Trump’s leadership, we’re expanding access to affordable medicines for millions of Americans.” CMS Administrator Dr. Mehmet Oz emphasized the model's goal of ensuring that Medicaid programs pay fair prices for prescription drugs, while CMS Innovation Center Director Abe Sutton noted that “drug prices in the U.S. remain far too high.”
Criticism & Opposition
Despite the optimistic outlook from the administration, some experts have raised concerns about the potential impact of the GENEROUS model. Critics argue that the model may not significantly lower prices, as Medicaid already benefits from substantial rebates from pharmaceutical companies. Additionally, there are questions regarding the model's implementation and whether it will effectively address the high costs of medications for all eligible beneficiaries.
Conflicting Reports & Gaps
While the administration projects substantial savings and increased access to medications, there is skepticism about how many individuals will actually benefit from the new pricing structure. Some experts have pointed out that the details surrounding eligibility for coverage under Medicare and Medicaid remain unclear, particularly for those seeking weight loss drugs. Furthermore, the long-term sustainability of the model and its effects on pharmaceutical innovation are yet to be fully assessed.
What's Next
The GENEROUS model is set to begin accepting applications from states in December 2025, with manufacturers required to apply by March 31, 2026. As the program rolls out, it will be crucial to monitor its effectiveness in reducing drug costs and improving access for Medicaid beneficiaries across the United States.
